Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,585 recruiting studies in this area right now.
By phase
- Not applicable9,775
- Phase 24,443
- Phase 12,736
- Phase 1/Phase 21,691
- Phase 31,397
- Phase 2/Phase 3281
- Phase 4262
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer651
- Colorectal Cancer495
- Lung Cancer424
- Ovarian Cancer340
- Multiple Myeloma333
- Gastric Cancer297
- Pancreatic Cancer293
- Acute Myeloid Leukemia292
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer224
- Endometrial Cancer206
- Advanced Solid Tumors192
- Bladder Cancer191
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University312
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)287
- Mayo Clinic242
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas637
- Arizona512
- Florida448
- Alabama418
- New York408
- Massachusetts342
- Maryland329
- New Jersey267
- Pennsylvania247
Recruiting studies20,585 total
- NCT05708235RecruitingPhase 2
Blood test monitoring for early breast cancer recurrence
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
A CoruñaAges 18 years+ - NCT07421700RecruitingPhase 1/Phase 2
Study of PF-08634404 alone or with enfortumab vedotin for bladder cancer
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Fayetteville, ArkansasAges 18 years+ - NCT06743581Recruiting
Cemiplimab and dupilumab before lung cancer surgery
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
Montreal, QuebecAges 18 years+ - NCT06218602RecruitingPhase 2
Fecal transplant for lymphoma patients getting CAR T therapy
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
Houston, TexasAges 18 years+ - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Chandler, ArizonaAges 18 years+ - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Springdale, ArkansasAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT06492486RecruitingPhase 2
Brain tumor radiation study using AI planning
This trial tests a new way to plan radiation therapy for brain tumors (gliomas) using artificial intelligence. It aims to make treatment more precise and personalized for people with either aggressive (GBM) or slower-growing (IDH-mutant) gliomas.
Mumbai, MaharatshtraAges 18–70 - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT07524855RecruitingPhase 1
HLD-0117 study for metastatic breast cancer
This early-stage study tests a new drug called HLD-0117 in women whose metastatic breast cancer (cancer that has spread beyond the breast) has stopped responding to previous hormone and targeted therapies. The goal is to see if this drug can slow or shrink the cancer in patients who have limited options left.
New Haven, ConnecticutAges 18 years+ - NCT06800053Recruiting
Support for LGBTQ+ cancer patients and caregivers
This study tests the FOCUS program, a support program designed for sexual and gender minority (LGBTQ+) cancer patients and their unpaid caregivers. It aims to help patients and caregivers cope with cancer through education and emotional support.
Detroit, MichiganAges 18–100 - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
La Jolla, CaliforniaAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Daphne, AlabamaAges 18 years+ - NCT07519655RecruitingPhase 1
New Cancer Drug Treatment for Advanced Lung, Esophageal, or Skin Cancer
This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.
Denver, ColoradoAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
Birmingham, AlabamaAges 18 years+ - NCT06869629Recruiting
Avoiding armpit lymph node removal in breast cancer
This trial tests whether it is safe to skip removing lymph nodes from the armpit when cancer has spread there but has been found by ultrasound. If you have breast cancer that has spread to armpit lymph nodes and are not getting chemotherapy before surgery, this study may be an option.
HelsinkiAges 18 years+ - NCT07331857Recruiting
Testing a new device for esophagus treatment
This study tests a new device (Digma System) for treating Barrett's esophagus and other esophageal conditions. It involves a short procedure during an endoscopy or surgery to remove abnormal tissue.
BrnoAges 18–70 - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT07401303Recruiting
Studying a new way to reduce risks during early stomach cancer surgery
This trial tests a technique called full-time RDI during ESD (a minimally invasive procedure to remove early stomach cancer). The goal is to see if it can lower the chance of serious side effects and shorten the procedure time. If you are scheduled for this surgery and meet the health requirements, you may be able to join.
Xi'an, ShaanxiAges 18–75 - NCT07140016RecruitingPhase 1
Study of gilteritinib for advanced ALK-positive lung cancer
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT06260514RecruitingPhase 1
New drug APR-1051 for advanced solid tumors
This trial tests a new drug called APR-1051 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and effective.
Houston, TexasAges 18 years+ - NCT07226999RecruitingPhase 2/Phase 3
A new study for people with extensive-stage small cell lung cancer using a study drug plus chemo
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Fayetteville, ArkansasAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,585 recruiting oncology studies from the U.S. registry right now, out of 31,101 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.